Nazione: Giordania
Lingua: inglese
Fonte: JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)
Doxorubicin Hcl 50 mg/25ml
مستودع ادوية الصباغ - Sabbagh Drug Store
L01DB01
Doxorubicin Hcl 50 mg/25ml
50 mg/25ml
1 Vial X 25ml
Fareva Unterach Gmbh/Austria (النمسا)
1 SUMMARY OF PRODUCT CHARACTERISTICS OF THE DRUG 1. NAME OF DRUG Doxorubicin Ebewe 2 mg/ml – vials 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml concentrate for the preparation of an infusion solution contains 2 mg doxorubicin in the form of doxorubicin hydrochloride. Other ingredients with known effect: 1 ml contains 9 mg sodium chloride. For the full list of ingredients, see section 6.1. 3. PHARMACEUTICAL FORM Concentrate for the production of an infusion solution. Clear, red solution pH value: 2.5 - 4 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Doxorubicin is used in adults, adolescents and children.  Mamma carcinoma  Neoadjuvant and adjuvant therapy of osteosarcoma  Advanced soft tissue sarcoma in adults  Small cell lung carcinoma (SCLC)  Hodgkin lymphoma  Highly malignant non-Hodgkin lymphoma  Induction and consolidation therapy for acute lymphatic leukaemia  Acute myeloblastic leukaemia  Advanced multiple myeloma  Advanced or recurring endometrium carcinoma  Advanced or recurring papillary / follicular thyroid carcinoma  Anaplastic thyroid carcinoma  Systemic treatment of localised advanced or metastasising carcinoma of the bladder  Intravesical prophylaxis against a recurrence of superficial carcinoma of the bladder following transurethral resection  Recurring ovarian carcinoma  Wilms tumour (at stage II in highly malignant forms, all advanced stages [III–IV])  Advanced neuroblastoma  Ewing sarcoma 2 Doxorubicin is often administered in combination chemotherapy dosing cycles in conjunction with other cytostatics. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Strictly for intravenous and intravesical application only. The vial should be at room temperature before piercing it with a needle. Doxorubicin may only be administered under the supervision of a qualified doctor experienced in cytostatics therapies. Patients must also be carefully and regularly monitored during treatment. Due to the risk of a fatal cardiomyopathy, the risks and advantag Leggi il documento completo